Literature DB >> 17303480

Determination of aciclovir and ganciclovir in human plasma by liquid chromatography-spectrofluorimetric detection and stability studies in blood samples.

N Perrottet1, A Beguin, P Meylan, M Pascual, O Manuel, T Buclin, J Biollaz, L A Decosterd.   

Abstract

A sensitive HPLC method has been developed for the assay of aciclovir and ganciclovir in human plasma, by HPLC coupled with spectrofluorimetric detection. Plasma (1000 microl), with 9-ethyl-guanine added as internal standard, is submitted to protein precipitation with trichloroacetic acid solution 20%. The supernatant, evaporated to dryness at 37 degrees C, is reconstituted in 100 microl of a solution of sodium heptanosulfonate 0.4% adjusted with acetic acid to pH 2.60 and a 30 microl volume is then injected onto a Nucleosil 100-5 microm C18 column. Aciclovir and ganciclovir are analysed by spectrofluorimetric detection set at 260 nm (excitation) and 380 nm (emission) using a gradient elution program with solvents constituted of acetonitrile and a solution of sodium heptanosulfonate 0.4% adjusted to pH 2.60. The calibration curves are linear between 0.1 and 10 microg/ml. The mean absolute recovery of aciclovir and ganciclovir are 99.2+/-2.5 and 100.3+/-2.5%, respectively. The method is precise (with mean inter-day C.V.s within 1.0-1.6% for aciclovir and 1.2-3.5% for ganciclovir), and accurate (range of inter-day deviations -1.6 to +1.6% for aciclovir and -0.4 to -1.4% for ganciclovir). The method has been applied in stability studies of ganciclovir in patients' blood samples, demonstrating its good stability in plasma at -20 degrees C and at room temperature. The distribution of ganciclovir and aciclovir in plasma and red blood cells was also investigated in vitro in spiking experiments with whole blood, which showed an initial drop of ganciclovir and aciclovir levels in plasma (about -25%) due to the cellular uptake of aciclovir and ganciclovir by red blood cells. The method has been validated and is currently applied in a clinical study assessing the ganciclovir plasma concentration variability after administration of valganciclovir in a population of solid organ transplant patients.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17303480     DOI: 10.1016/j.jchromb.2007.01.045

Source DB:  PubMed          Journal:  J Chromatogr B Analyt Technol Biomed Life Sci        ISSN: 1570-0232            Impact factor:   3.205


  8 in total

1.  Multiplex ultra-performance liquid chromatography-tandem mass spectrometry method for simultaneous quantification in human plasma of fluconazole, itraconazole, hydroxyitraconazole, posaconazole, voriconazole, voriconazole-N-oxide, anidulafungin, and caspofungin.

Authors:  Laurent Arthur Decosterd; Bertrand Rochat; Benoît Pesse; Thomas Mercier; Frédéric Tissot; Nicolas Widmer; Jacques Bille; Thierry Calandra; Boris Zanolari; Oscar Marchetti
Journal:  Antimicrob Agents Chemother       Date:  2010-09-20       Impact factor: 5.191

2.  Simultaneous determination of acyclovir, ganciclovir, and (R)-9-[4-hydroxy-2-(hydroxymethyl)butyl]guanine in human plasma using high-performance liquid chromatography.

Authors:  Dennis R Weller; Henry H Balfour; Heather E Vezina
Journal:  Biomed Chromatogr       Date:  2009-08       Impact factor: 1.902

Review 3.  Valganciclovir in adult solid organ transplant recipients: pharmacokinetic and pharmacodynamic characteristics and clinical interpretation of plasma concentration measurements.

Authors:  Nancy Perrottet; Laurent A Decosterd; Pascal Meylan; Manuel Pascual; Jerome Biollaz; Thierry Buclin
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

4.  Population pharmacokinetics of ganciclovir in solid-organ transplant recipients receiving oral valganciclovir.

Authors:  N Perrottet; C Csajka; M Pascual; O Manuel; F Lamoth; P Meylan; J D Aubert; J P Venetz; P Soccal; L A Decosterd; J Biollaz; T Buclin
Journal:  Antimicrob Agents Chemother       Date:  2009-03-23       Impact factor: 5.191

5.  Determination of Acyclovir in Human Plasma Samples by HPLC Method with UV Detection: Application to Single-Dose Pharmacokinetic Study.

Authors:  Dragica Zendelovska; Suzana Simeska; Emilija Atanasovska; Kalina Georgievska; Igor Kikerkov; Nikola Labachevski; Krume Jakovski; Trajan Balkanov
Journal:  Open Access Maced J Med Sci       Date:  2015-01-22

6.  Intensive Hemodiafiltration Successfully Removes Ganciclovir Overdose and Largely Exceeds Reported Elimination During Hemodialysis-A Case Report and Review of the Literature.

Authors:  Verena Gotta; Anne Leuppi-Taegtmeyer; Mirjam Gessler; Marc Pfister; Daniel Müller; Andreas Werner Jehle
Journal:  Front Pharmacol       Date:  2020-06-12       Impact factor: 5.810

Review 7.  Therapeutic Drug Monitoring of Ganciclovir: Where Are We?

Authors:  Anne-Grete Märtson; Angela E Edwina; Hannah Yejin Kim; Marjolein Knoester; Daan J Touw; Marieke G G Sturkenboom; Jan-Willem C Alffenaar
Journal:  Ther Drug Monit       Date:  2022-02-01       Impact factor: 3.118

8.  Variable viral clearance despite adequate ganciclovir plasma levels during valganciclovir treatment for cytomegalovirus disease in D+/R- transplant recipients.

Authors:  Nancy Perrottet; Oriol Manuel; Frédéric Lamoth; Jean-Pierre Venetz; Roland Sahli; Laurent A Decosterd; Thierry Buclin; Manuel Pascual; Pascal Meylan
Journal:  BMC Infect Dis       Date:  2010-01-06       Impact factor: 3.090

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.